Powerlifting Athlete Suspended for Presence of Higenamine
26th February 2019
The Canadian Centre for Ethics in Sport (CCES) announced today that David Lee, a powerlifting athlete, received a 14-month sanction for an anti-doping rule violation. The athlete’s urine sample, collected during in-competition doping control on August 11, 2018, revealed the presence of higenamine, a beta-2 agonist.
Higenamine is classified as a “specified substance” on the Prohibited List. Under the rules of the Canadian Anti-Doping Program (CADP), an athlete facing a first violation involving a “specified substance” will be given a proposed sanction based on the CCES’s assessment of the athlete's degree of fault. In this case, the CCES proposed a 14-month period of ineligibility.
In response to the CCES’s notification of the adverse analytical finding, Mr. Lee admitted the violation in a timely fashion (in accordance with CADP rule 10.11.2), waived his right to a hearing and accepted the proposed sanction, which terminates on October 10, 2019. During the sanction period, the athlete, who resides in Kelowna, BC, is ineligible to participate in any capacity with any sport signatory to the CADP, including training with teammates.
In compliance with rule 7.10 of the CADP, the CCES’s file outcome summary can be found at www.cces.ca/sanctionreg.
- Tags: Anti-Doping | Canada | Canadian Anti-Doping Program (CADP) | Canadian Centre for Ethics in Sport (CCES) | Higenamine | Powerlifting | Weightlifting